Goldman initiated coverage on Schrodinger with a new price target
$SDGR
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $23.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2025 | $20.00 | Buy → Neutral | Citigroup |
| 8/14/2025 | $25.00 | Overweight | Barclays |
| 7/3/2025 | $28.00 | Equal-Weight | Morgan Stanley |
| 7/2/2024 | $29.00 | Outperform | Leerink Partners |
| 12/5/2023 | $38.00 | Overweight | KeyBanc Capital Markets |
| 5/5/2023 | $60.00 | Overweight | Piper Sandler |
| 12/19/2022 | $23.00 | Neutral | Goldman |
| 3/1/2022 | $55.00 | Buy | Citigroup |
Schrödinger, Inc. (NASDAQ:SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs ve
Schrödinger, Inc. (NASDAQ:SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, Schrödinger believes the path to development as a combination therapy would be difficult to pursue. The Phase 1 study was supported by preclinical data which had dem
Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c
Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00
Barclays initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $25.00
Morgan Stanley resumed coverage of Schrodinger with a rating of Equal-Weight and set a new price target of $28.00
10-Q - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w
Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c
Schrödinger (NASDAQ:SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, phar
SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed across a broad range of B-cell malignancies, including monotherapy responses in patients with CLL and Waldenström macroglobulinemia Management to host a webcast today at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in mul